Sugi Predict

Sugi Predict / Compounds / SCHEMBL1409293

SCHEMBL1409293

SCHEMBL1409293

CCOC(=O)CC(C)(C)N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.50
▸ MGAM O43451 1/20 0.50
▸ SI P14410 1/20 0.50
▸ MGAM2 Q2M2H8 1/20 0.50
▸ ALDH1A1 P00352 6/20 0.46
▸ TRPA1 O75762 1/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ GSK3A P49840 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ SOAT1 P35610 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL944681 0.98 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL7815798 0.82 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL27802055 0.81 SOAT1 (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28789563 0.80 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL21052480 0.80 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL798062 0.80 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL232993 0.80 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL16276945 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL10099129 0.79 GAA (0.43) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL7822673 0.79 GAA (0.43) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0983037-B1 ANTIFUNGAL NAIL LACQUER MACROCHEM CORP (US) 2003-05-02 — — EP claimed
US-6224887-B1 MIXTURE CONTAINING PENETRATION PROMOTER, WATER INSOLUBLE FILM FORMING POLYMER AND SOLVENT MACROCHEM CORPORATION 2001-05-01 — — US claimed
EP-0983037-A4 ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME MACROCHEM CORP (US) 2000-04-26 — — EP claimed
EP-0983037-A1 ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME MacroChem Corporation (US) 2000-03-08 — — EP claimed
WO-1999039680-A1 ANTIFUNGAL NAIL LACQUER AND METHOD USING SAME MACROCHEM CORPORATION (US) 1999-08-12 — — WO claimed
EP-4724441-A1 ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF Revir Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
US-12473290-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses BRISTOL MYERS-SQUIBB COMPANY (US) 2025-11-18 — — US disclosed
WO-2024251211-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 REVIR THERAPEUTICS, INC. (US) 2024-12-12 — — WO disclosed
WO-2024251212-A1 ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF REVIR THERAPEUTICS, INC. (US) 2024-12-12 — — WO disclosed
EP-3935058-B1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2024-08-21 — — EP disclosed
CN-114222744-B Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response 百时美施贵宝公司 2024-06-25 — — CN disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 — — US disclosed
WO-1990012804-A2 PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS THE UPJOHN COMPANY (US) 1990-11-01 — — WO disclosed
US-4704389-A ANXIOLYTIC, HYPOTENSIVE MERRELL DOW PHARMACEUTICALS INC. (US) 1987-11-03 — — US disclosed
EP-0238905-A2 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1987-09-30 — — EP disclosed
US-4696927-A 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1987-09-29 — — US disclosed
EP-0236931-A2 Aromatic omega-alkylimino-tetrahydro-6H-1,3-Thiazin-6-one derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1987-09-16 — — EP disclosed
EP-0081581-B1 COMPOSITIONS FOR TREATING GLAUCOMA AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1986-12-30 — — EP disclosed
US-4559359-A Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1985-12-17 — — US disclosed
US-4455317-A Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1984-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR GAA 1526/4885MGAM 1964/4885SI 547/4885
US-12473290-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses TYK2, JAK3, IFNAR1 GAA 3722/4885MGAM 2604/4885SI 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.